Global

Billions of dollars and countless hours of research have been poured into fighting the scourge of cancer. But the work has yielded little tangible benefit.

An international analysis.

A 66% price slash of a little used but powerful drug that prevents tuberculosis (TB) could help stave off the deadly lung disease in millions of people around the world.

Today, three companies control virtually the entire global market for insulin.

Financial conflict of interest in cancer medicine matters. The pharmaceutical industry is run by intelligent people who choose to pay physicians millions of dollars. It is hard to believe they have not calculated that this aids their bottom lines.

Some diseases affect billions, yet they attract little interest from the pharmaceutical industry and public sector because those affected are poor, leaving doctors powerless to treat patients.

Key lessons, challenges, and opportunities for the future.

Corporate Power, Public Power, and the Future of Prescription Drug Policy in the United States

The world’s most expensive drug - a record price tag of $2.1 million, or an annualized cost of $425,000 per year for five years - has been used to treat 100 patients since its launch and brought in $160 million for its maker.

Sales beat expectations despite data-manipulation scandal.

A bill introduced last year in the US House of Representatives that would reward manufacturers of certain novel antibiotics with transferrable market exclusivity vouchers could end up costing public and private payers $4.5 billion over 10 years.

New triple combination cystic fibrosis drug priced at $311,000 per year.

Antibiotics are a pillar of modern medicine. They have saved millions of lives. But as the use of antibiotics has increased, so has the proliferation of antibiotic-resistant microbes that have adapted to survive most, or all, of today’s antibiotics.

Predictions and Solutions for a Global Obesity Epidemic